Healthcare industry

Press release - 23/07/2009

Mannheim Medical Centre – leading cancer laboratory and clinical research centre

Mannheim is the only medical centre in Germany to fulfil the criteria of an affiliated centre of EORTC. According to a recent EORTC report Mannheim is the only German centre that has fulfilled the organisations high quality criteria over the last three years.

Article - 02/07/2009

A virus that hides while it waits for an opportunity to replicate

Thomas Mertens, Medical Director of the Institute of Virology in Ulm, has a strong scientific and clinical interest in the human cytomegalovirus (HCMV), a big virus with a big impact which, despite its size, is overshadowed by known viruses such as the HI virus that is the object of research for Mertens’ colleagues. HCMV research is a challenging area where quick successes are rare.

Press release - 30/06/2009

Gentle rather than radical: ways to improve the treatment of autoimmune diseases

Autoimmune diseases are usually treated with drugs that block the entire immune system rendering the body very susceptible to all kinds of infections. A team of Constance researchers under the leadership of Prof. Marcus Groettrup has developed a treatment method that only targets part of the immune system and is therefore far better tolerated by patients.

Press release - 24/06/2009

Artificial liver for drug testing

The liver is one of the most important metabolic organs in humans. Johanna Schanz and Heike Mertsching, two scientists from Fraunhofer have developed a model of the liver that is both viable outside the body and suitable for testing drugs. For their work, the two researchers have been awarded the Technology for People award, along with a cheque for 10,000 euros.

Press release - 28/05/2009

CureVac Begins Clinical Study with mRNA Vaccine

CureVac GmbH announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the Clinical Trial Application (CTA) to begin a Phase I clinical study with RNActive® derived mRNA vaccine CV9201. The vaccine will be tested in patients with advanced non-small cell lung cancer who have been pre-treated with different therapies.

Press release - 26/03/2009

Sygnis Pharma AG increases capital

SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

Article - 17/02/2009

Tissue engineering companies and EU obstacles

With the new regulation on advanced therapy medicinal products the European Union has tried to establish legal certainty with regard to gene therapy somatic cell therapy and tissue engineering products. However Dr. Heinz W. Joseph of TETEC AG is sure that the new guidelines will lead to problems for small and medium-sized companies.

At present active immunotherapy seems to produce the best results in the treatment of cancer. The Tübingen-based biotech company CureVac is now hoping to achieve a breakthrough in cancer therapy with a worldwide unique vaccine. The first clinical trials have recently commenced.

CureVac Receives IND Approval from the FDA to start its Phase I/IIa mRNA Vaccine Clinical Trial in Prostate Cancer.

Article - 14/01/2009

Strict requirements for the market approval of tissue engineering products

New regulations for the marketing approval of advanced therapy medicinal products have applied in the EU since December 2008. Prof. Sabine Kloth from TÜV SÜD Product Service GmbH is an expert in materials of animal origin and has been closely following the formulation of the ATMP Regulation.

Protein kinases are a major focus of modern cancer research. Since it has become known that these enzymes play a role in the development of tumours, researchers around the world are concentrating on finding drugs to inhibit overactive protein kinases and prevent cancer cells from growing. One of these active substances is currently being tested at the Tumour Biology Centre in Freiburg as part of a worldwide phase III clinical trial.

The German regulatory authority has approved the Clinical Trial Application CTA to begin a Phase I clinical study with RNActive - derived mRNA vaccine CV9103. It will be tested in patients with hormone-refractory metastatic prostate cancer.

The actual age of a person not only depends on the date he or she was born. Biological age, which is far more important in determining lifespan, can so far only be estimated rather than precisely calculated. The European MARK-AGE research project is working on finding a solution to this problem. Esslingen plays a major role in this project for two reasons: the structure of the city and the company BioTeSys.

Karen Grave-Hermann and Dr. Robert Hermann founded cr.applications in 2003. The two specialists who have wide-ranging experience in drug development talked to Michael Statnik about current trends in their field and about the development of the German biotech sector.

Boehringer Ingelheim has three oral compounds for the treatment of diabetes type II in phase II and III of clinical development. The most advanced compound a DPP-4 inhibitor is in the final clinical phase.

A consortium is providing funding for the development of Phenex drug candidates for type 2 diabetes and metabolic syndrome. Phenex will take its metabolic syndrome drug candidates into Phase I clinical testing by early 2010 at the latest.

Duchenne muscular dystrophy DMD is a severe disease affecting boys characterised by rapid progression of muscle degeneration so that boys as young as 10 to 12 years of age have to use a wheelchair and leading to death in young men. In Germany about 2500 children and young adults suffer from DMD.

The Lake Constance region offers a broad range of cancer therapies and is home to several institutes and companies that are dealing with cancer research. The BioLAGO biotechnology network offers them a joint platform for co-operation and exchange of information.

The medical importance of vitamin D calciferol is most likely even higher than suggested by recently published studies. A study which also involves the endocrinologist Bernhard Böhm from Ulm has attracted enormous attention as it suggests that vitamin D deficiency increases mortality.

Under the agreement Nycomed will receive the exclusive worldwide rights to develop manufacture and commercialise the subcutaneous formulation of veltuzumab for the treatment of all non-cancer indications.

Frank Kirchhoff an AIDS researcher from Ulm has learnt to pose important questions and find the right answers during his post-graduate studies. This recipe has brought him and his research group international recognition and makes him one of the best AIDS researchers worldwide. Important publications within a very short time and numerous awards are clear evidence of his outstanding achievements. In addition he has just started a clinical trial…

About a year ago Prof. Dr. Martin Schwemmle and his team at the University Hospital of Freiburg discovered a new starting point in the fight against the H5N1-virus. In the meantime the scientists are working together with the company Pike Pharma to develop a compound.

DFG and BMBF will provide 15 million euros per year each starting in 2009.

CureVac GmbH has entered into a partnership with the Department of Urology University of Florida Gainesville U.S. to jointly advance its lead candidate CV9103 into the clinical development. The alliance covers preclinical studies and a US phase III trial.

Article - 28/04/2008

A milestone in the treatment of leukaemia

Blood cancer experts in the team of Professor Peter Dreger Head of the Section of Allogeneic Stem Cell Transplantation at the University Hospital of Heidelberg have achieved a major success in the treatment of leukaemia. For the 500th time the physicians from the Department of Haematology Oncology and Rheumatology transferred blood stem cells from a healthy donor to a patient suffering from leukaemia or lymphoma.